Julie Rubinstein, Adaptive Biotechnologies COO, sells $1M in stock

Julie Rubinstein, the President and COO of Adaptive Biotechnologies Corp, recently sold a total of approximately $1,047,303 worth of the company's common stock over several transactions in mid-November 2026. These sales were made under a Rule 10b5-1 trading plan and included the exercise of stock options, which were fully vested and exercisable.

The reported transactions involved the sale of 23,338 shares at various prices ranging from $28.43 to $31.63. Despite these sales, Adaptive Biotechnologies reported a significant increase in its third-quarter revenue for 2026, reaching $83.9 million, which surpassed Wall Street analysts' expectations. The company's early profitability and the positive reaction in after-hours trading underscore the company's strong financial performance.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.